Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  5.00 0.89% 565.00 555.00 570.00 575.00 562.50 562.50 76,880 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 336

Renalytix Ai Share Discussion Threads

Showing 126 to 149 of 300 messages
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
Yes, it seems highly likely that some money will be raised. It will be interesting to see how much or if it's token to provide some liquidity.Presumably the spin off will take place ASAP and before the new listing.
It's also a public offering, so one assumes it's a potential capital raise too?
This announcement contains inside information Renalytix AI plc ("RenalytixAI", the "Company") Proposed dual-listing on Nasdaq Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of American Depositary Shares, each of which will represent one or a number of the Company's ordinary shares, on the Nasdaq Stock Market (the "Offering").
New initiation from Investec with 523p price target.
I challenged Barclays Smart Investor today,as they are still listing Renalytix as restricted (unable to buy and offering a sell as the only option). They have come back to me and said that it had already been escalated by others, and that they checked again today and Crest has still 'not' yet removed the restriction!
Hopefully there will be a subscription option for shareholders too. I significantly added to my RENX holding at that time.
I can tell you from a very poor experience, that not just Americans were excluded from buying the shares, but UK investors too i.e. those of us who are with incompetent brokers that were unable to differentiate their US clients from their UK clients, which beggars belief considering the personal information that they hold! It's a shame that this was not done much earlier and hopefully this will apply to the demerger (if completed)of Fractal Dx into Verici Dx My EKF Renalytix demerger holding remains fully intact/invested.
Looking at how well it paid off for EKF investors when they split out RENX it's not a bad shout. Also if I understand today's news correctly it opens up RENX purchases to Americans who in my opinion will be more likely to value the business higher on the news so far. Medicare and fda breakthrough device news in my opinion particularly undervalued at the moment
Hi All, Hope you are all surviving these difficult times. Re: the demerger of the new enterprise. Does anyone know what the cut off date is for qualifying for new shares? The General Meeting is on 15th May and the effective date is 10th June. Given the performance of RENX it might be a good plan to acquire some more now to qualify for extra shares. Any thoughts on this? CD
Off the radar somewhat currently, but Renalytix continues to make good progress. Plus we have a potential demerger for good measure, which the market appears to be waking up to.
Does anyone have any idea approximately when an FDA update is expected? I can’t seem to find anything in the RNS history?
Very pleased to see further strategic progress being made.
Renalytix AI plc is being highlighted as a successful AIM story by the London Stock Exchange - An IPO on AIM helped Renalytix secure their long-term health RenalytixAI's diagnostic products could change the lives of millions who suffer from kidney disease. Joining AIM has been central to the strategy of this emerging growth company. hTTps://
Renalytix AI PLC Presentation of KidneyIntelX Health Economics DataSource: RNS Non-RegulatoryTIDMRENXRenalytix AI PLC27 March 2020Renalytix AI plc("RenalytixAI", the "Company") Presentation of KidneyIntelX(TM) Health Economics Data Renalytix AI plc (LSE : RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that further to RNS Reach 2937H on 24 March 2020, Boston Healthcare Associates has presented data on KidneyIntelX(TM) , the Company's AI-enabled in vitro diagnostic test for kidney disease, and the clinical and health economic benefit from deploying the test in large health systems in the United States during National Kidney Foundation's Spring Clinical Meeting.A poster summarizing the data presented by Boston Healthcare is now available through the conference website and at .It is estimated that there are 12 million individuals with diabetic kidney disease (DKD) in the United States alone. The economic impact model estimates that KidneyIntelX(TM) testing of 100,000 individuals with DKD, with the assumption of a 20% relative decrease in DKD progression for the 16% of DKD individuals scored as "high-risk" by KidneyIntelX(TM) patients, could deliver cumulative savings of more $1 billion over a five-year period. The presentation was delivered by Thomas Goss, PharmD, Senior Vice President, Boston Healthcare Associates.During the presentation, Dr. Goss described the population health benefits that can be realized with system-wide adoption of KidneyIntelX(TM) . These include delaying progression to more advanced stages of DKD, reducing hospitalizations, and avoiding unplanned emergency room crashes onto dialysis, and delaying or preventing end stage kidney disease, and related dialysis and kidney transplant procedures. These outcomes will not only lead to a significant improvement in quality of life for diabetic kidney disease patients, they also can drive significant cost benefit for health providers and insurers. The model developed by Boston Healthcare demonstrates that a health insurer will realize net savings in less than two years, assuming a one-time use of the test. Based on 100,000 patients tested, annual savings increase each year and peak at $685 million in year five. This combination of significantly improved patient outcomes, optimal utilization of healthcare resources, and savings for health insurers is expected to lead to an increase in coverage determinations for KidneyIntelX(TM) from private insurers in the United States in both 2020 and 2021.NKF's Spring Clinical Meeting gathers more than 3,000 nephrology healthcare professionals from across the United States to learn about the newest developments related to all aspects of nephrology practice. Due to the coronavirus and coronavirus disease (COVID-19) outbreak in the United States the meeting is being held as a live virtual event in 2020. Sessions can be accessed through the conference website. For information about the NKF's virtual conference event, visit .
Being a realist cynic - If those with kidney problems have a very significanly higher risk profile of dying from the virus might not much of the potential market be removed? OK- PI but likely?
This post is a test as the thread seems to be suck - so please ignore
AI testing on covid 19
The Presentation(March 2020)from last week in the US and last night in the UK, is now available on the Renalytix website - hTTps://
All other positive developments and progress aside, I was not expecting the potential spin-out and admission to AIM of FractalDX, which could deliver further value. Future developments and outlook section provides an insightful read and the following excerpt is ringing loud in my ears - "We continue to believe that the macro environment for kidney disease has undergone disruptive positive change in the past year. Our own market-based experience has suggested an increasing level of urgency from large medical stakeholders to improve diagnosis and prognosis in earlier stages of kidney disease (stages 1, 2 and 3) for better health economics and patient outcomes."
And on the same date as the Presentation in the US, Renalytix will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020. Put another way, a US and UK investor Results briefing. Renalytix gets a strong mention in CNBC article - A major breakthrough for the millions of Americans on the brink of kidney failure and dialysis PUBLISHED TUE, FEB 25 2020 KEY POINTS RenalytixAI has developed an artificial intelligence clinical diagnostic that rates a person’s chances of getting kidney disease. The tool, called KidneyIntelX, is expected to launch in the second quarter of this year. The company has also developed FractalDX, a lab-based AI tool that can predict the risk of adverse transplant outcomes, including early kidney rejection. The U.S. spends about $100 billion annually to treat the nearly 40 million Americans suffering from chronic kidney disease who need dialysis and organ transplants. Medical experts are hoping 2020 will mark a turning point in the fight against kidney disease in America, thanks to advancing technology. Currently, the U.S. spends about $100 billion annually to treat the nearly 40 million Americans suffering from chronic kidney disease who need dialysis and organ transplants. The public health crisis, exacerbated by the rise in obesity and type 2 diabetes, is now the ninth leading cause of death in the nation, according to the Centers for Disease Control and Prevention. One company making inroads in the field is RenalytixAI, an AI clinical diagnostics company for kidney disease. It has received an FDA breakthrough device designation for its KidneyIntelX, an AI-powered diagnostic product for kidney disease that is expected to launch in the second quarter of this year in the U.S. Full story - hTTps://
Slightly intrigued that an announcement of a presentation was via an RNS as opposed to an RNS-Non-Regulatory. Anyway, I look forward to the presentation on Tuesday 3 March, which will be made available on Renalytix website.
According to a new paper, Kidney disease risk reduced by SGLT2 inhibitors. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials. KidneyIntelX will thus be of particular interest to large pharma's efforts in terms of supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes(as well as patient stratification for drug clinical trials). 18 FEBRUARY 2020 In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes hTTps://
Further evidence supporting screening of at risk groups (and potentially beyond) - Almost half of over-60s with CKD are undiagnosed, research suggests 18 February 2020 Almost half of over-60s with chronic kidney disease may be undiagnosed, according to new research. In response, there 'could be value' in checking kidney function in patients with conditions such as hypertension or diabetes. Primary care researchers in Oxford have found that the prevalence of CKD in people aged over 60 is around 18% and that almost half of these patients would be undiagnosed without screening. Full story -
Waiting for some positive news on this one anytime now
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200706 18:42:36